<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008552</url>
  </required_header>
  <id_info>
    <org_study_id>MEDIAGENE</org_study_id>
    <nct_id>NCT02008552</nct_id>
  </id_info>
  <brief_title>Study of the Effect of the Benfluorex</brief_title>
  <acronym>MEDIAGENE</acronym>
  <official_title>Research for Genetic Factors Involved in the Individual Susceptibility to Develop a Valvulopathy During a Medicinal Exposure in the Benfluorex.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 5 million persons in France exposed, in last years, to the taking of the
      Benfluorex.

      Arisen, at certain patients, of a valvulopathy characterized by mitrals and/or aortic leaks
      Withdrawal of the French market: nov. 2009 Only a percentage limited by exposed patients
      developed a severe valvulopathy (1/1000), whereas on the contrary, many patients were
      exposed during years without developing the slightest anomaly.

      The hypothesis is the existence of a particular genetic susceptibility at the patients
      having developed a valvulopathy continuation in the exposure in this medicine.

      Existence of one varying genetics with strong effect. The purpose is to identify involved
      genetic factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Identify the genetic factors</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identify the genetic factors involved in the individual susceptibility to develop a valvulopathy during a medicinal exposure in the benfluorex.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the quality of life</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the quality of life of the cases and the witnesses via the completion of Two validated questionnaires of quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Sampling of Blood</condition>
  <arm_group>
    <arm_group_label>Mediagene</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sampling blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sampling of blood</intervention_name>
    <description>Sampling of blood was taken and analyse to research factor genetic</description>
    <arm_group_label>Mediagene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of the cases :

          -  Individual presenting a typical medicinal valvulopathy defined by:

          -  A previous exposure of at least 6 months in the benfluorex or occasional exposure
             accepted about is the posology. The preliminary exposure in the dexfenfluramine or in
             the fenfluramine is authorized.

          -  A picture board of insufficiency mitral restrictive and/or aortic restrictive (in
             echocardiography) typical of a medicinal achievement, an average gravity in severe
             (rank II - IV), without cause associated of valvulopathy (no calcification, no
             atypical aspect) with compatible macroscopic and histological aspect (for the
             operated patients).

          -  Individual followed in one of the sites of study or recruited via associations AVIM
             and CADUS.

          -  Individual of Caucasian origin

          -  Individual having signed the form of specific consent for the study individual .

        Inclusion criteria of witnesses :

          -  Individual presenting an exposure previous to the benfluorex superior or equal to the
             equivalent of 2 years of treatment in 3 tablets a day and pursued to 2 years
             preceding the realization of a cardiac echography of screening. The preliminary
             exposure in the dexfenfluramine or in the fenfluramine is authorized.

          -  Individual presenting a strictly normal cardiac echography in particular: absence of
             valvulopathy significant, of morphological valvular anomaly (event without
             echography) and of valvular, including &quot;trivial&quot; leak at the aortic level. The
             mitrals micro leaks &quot;physiological&quot; are accepted.

          -  Individual having been seen for screening in one of the sites of study or having been
             included in the forward-looking study coordinated by Pr. TRIBOUILLOY (which the
             objective is to compare the echography data of a group of patients having been
             treated at least 3 months in the benfluorex and with a group of patients diabetics
             having never received this medicine).

          -  Individual of Caucasian origin.

          -  Individual having signed the form of specific consent for the study

        Exclusion criteria of the cases:

          -  Individual presenting another associated heart disorder.

          -  Individual having been exposed to another agonists of the receivers 5-HT2B such as
             the pergolide, the cabergoline, the lisuride, the quibbled by-products or the
             ecstasy.

          -  Individual having explicitly refused to participate in the study.

        Exclusion criteria of witnesses :

        - Individual having explicitly refused to participate in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irène Frachon, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Brize</last_name>
    <email>patricia.brize@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irène Frachon, PH</last_name>
    <email>irene.frachon@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Sud Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Tribouilloy, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Tribouilloy, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irène FRACHON, PH</last_name>
    </contact>
    <investigator>
      <last_name>Irène FRACHON, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Jobic, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Etienne, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Côte de Nacre Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculté de médecine Toulouse</name>
      <address>
        <city>France</city>
        <zip>31073</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atul Pathak, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Louis Montastruc, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atul Pathak, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Habib, PUPH</last_name>
    </contact>
    <investigator>
      <last_name>Gilbert Habib, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Thorax Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Gueffet, PH</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Gueffet, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Letrourneau, puph</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>November 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic factor</keyword>
  <keyword>Valvulopathy</keyword>
  <keyword>Mediator</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benfluorex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
